<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(9)</volume><submitter>Hung NV</submitter><pubmed_abstract>Alzheimer's disease (AD) is associated with AChE and BACE1 enzymes. Designing inhibitors for preventing these enzymes can be benefit for AD treatment. In this context, theophylline derivatives were generated to prevent the biological activity of AChE and BACE1. In particular, the potential inhibitory of these compounds was rapidly and accurately estimated &lt;i>via&lt;/i> knowledge-methods. The &lt;i>in vitro&lt;/i> tests were then performed to validate the artificial intelligent approach. Among these, compound 12 exhibited the most potent AChE inhibition with an IC&lt;sub>50&lt;/sub> of 15.68 μM, while showing limited activity against BACE1. In addition, six compounds were indicated that are able to inhibit AChE, however, the theophylline derivatives play poor performance over the BACE1 target. Atomistic s</pubmed_abstract><journal>RSC advances</journal><pagination>6994-7003</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11877286</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Discovery of novel theophylline derivatives bearing tetrazole scaffold for the treatment of Alzheimer's disease.</pubmed_title><pmcid>PMC11877286</pmcid><pubmed_authors>Hien TTT</pubmed_authors><pubmed_authors>Tran PT</pubmed_authors><pubmed_authors>Nguyen TH</pubmed_authors><pubmed_authors>Hung NV</pubmed_authors><pubmed_authors>Thai QM</pubmed_authors><pubmed_authors>Hai Linh VN</pubmed_authors><pubmed_authors>Quoc Tien L</pubmed_authors><pubmed_authors>Ngo ST</pubmed_authors><pubmed_authors>Hoang VH</pubmed_authors><pubmed_authors>Nguyen TX</pubmed_authors><pubmed_authors>Tran H</pubmed_authors><pubmed_authors>Nguyen TK</pubmed_authors><pubmed_authors>Pham DV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery of novel theophylline derivatives bearing tetrazole scaffold for the treatment of Alzheimer's disease.</name><description>Alzheimer's disease (AD) is associated with AChE and BACE1 enzymes. Designing inhibitors for preventing these enzymes can be benefit for AD treatment. In this context, theophylline derivatives were generated to prevent the biological activity of AChE and BACE1. In particular, the potential inhibitory of these compounds was rapidly and accurately estimated &lt;i>via&lt;/i> knowledge-methods. The &lt;i>in vitro&lt;/i> tests were then performed to validate the artificial intelligent approach. Among these, compound 12 exhibited the most potent AChE inhibition with an IC&lt;sub>50&lt;/sub> of 15.68 μM, while showing limited activity against BACE1. In addition, six compounds were indicated that are able to inhibit AChE, however, the theophylline derivatives play poor performance over the BACE1 target. Atomistic s</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-02T00:00:42.882Z</modification><creation>2025-04-04T20:25:02.727Z</creation></dates><accession>S-EPMC11877286</accession><cross_references><pubmed>40041377</pubmed><doi>10.1039/d5ra00488h</doi></cross_references></HashMap>